NCT01573468 - Capecitabine/Tesetaxel Versus Capecitabine/Placebo as Second-line Therapy for Gastric Cancer | Biotech Hunter

Enrollment

580

Participants

Timeline

Start Date

April 30, 2012

Primary Completion Date

July 31, 2014

Study Completion Date

August 31, 2014

Conditions

Gastric Carcinoma

Interventions

DRUG

Tesetaxel

Tesetaxel 27 mg/m2 orally once on Day 1 of each cycle

DRUG

Placebo

Placebo orally once on Day 1 of each cycle

DRUG

Capecitabine

Capecitabine 1750 mg/m2/day orally twice daily (in 2 equally divided doses) on Days 1-14 of each cycle

Trial Locations (3)

RECRUITING

National Cheng Kung University Hospital, Tainan City

RECRUITING

Krankenhaus Nordwest, Frankfurt

RECRUITING

The University of Texas MD Anderson Cancer Center, Houston